DEXACORT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Sep 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXACORT is a metered-dose aerosol inhaled corticosteroid approved in 1962 by UCB Pharma. The generic mechanism of action and specific indications are not publicly detailed in available data, but the inhalation route suggests respiratory or airway inflammation treatment. As a legacy small-molecule product, it represents a mature therapeutic option in its class.
LOE Approaching
With LOE approaching and competitive pressure at 30%, this product faces significant generic/biosimilar erosion; expect lean commercial teams focused on legacy account management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DEXACORT offers limited career advancement potential due to approaching LOE and zero linked job openings. Working on this product typically involves defensive commercial strategy, cost management, and maintaining legacy accounts rather than driving innovation or expansion.
Brand ManagerCommercial Operations Manager
Worked on DEXACORT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.